Amifostine inhibits angiogenesis in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 304, Issue 2, 2003, Pages 729-737

  Giannopoulou, Efstathia ^a   Katsoris, Panagiotis ^a   Kardamakis, Dimitris ^a   Papadimitriou, Evangelia ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; ANGIOGENESIS INHIBITOR; ANTIMETASTATIC AGENT; ANTINEOPLASTIC AGENT; COLLAGEN TYPE 1; DRUG METABOLITE; LAMININ; MESSENGER RNA; NITRIC OXIDE SYNTHASE; PLASMIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; CHICKEN; CHORIOALLANTOIS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; EMBRYO; EXTRACELLULAR MATRIX; GENE EXPRESSION; IN VIVO STUDY; METASTASIS INHIBITION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RADIATION PROTECTION; TOXICITY; X RAY;

AMIFOSTINE; ANGIOGENESIS INHIBITORS; ANIMALS; CHICK EMBRYO; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL GROWTH FACTORS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037308079     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.042838     Document Type: Article

References (40)

1. Ausprunk DH, Dethlefsen SM, and Higgins ER (1991) Distribution of fibronectin, laminin and type IV collagen during development of blood vessels in the chicken chorioallantoic membrane, in The Development of the Vascular System (Feinberg RN, Sherer GK, and Auerbach R eds) pp 93-108, Karger, Basel.
2. Baldi A, Savoini G, Cheli F, Fantuz F, Senatore E, Bertocchi L, and Politis I (1996) Changes in plasmin-plasminogen-plasminogen activator system in milk from Italian fresian herds. Int Dairy J 6:1045-1053.
3. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
4. Capizzi RL (1996) The preclinical basis for broad spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol®). Eur J Cancer 32:S5-S16.
5. Capizzi RL and Oster W (2000) Chemoprotective and radioprotective effects of amifostine: an update of clinical trials. Int J Hematol 72:425-435.
6. Carmeliet P and Jain RK (2000) Angiogenesis in cancer and other diseases. Nature (Lond) 407:249-257.
7. Dorr RT (1998) Radioprotectants: pharmacology and clinical applications of amifostine. Semin Radiat Oncol 8:10-13.
8. Ferrara N and Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18:4-25.
9. Fukumura D and Jain RK (1998) Role of nitric oxide in angiogenesis and microcirculation in tumors. Cancer Metastasis Rev 17:77-89.
10. Fukumura D, Takeshi G, Kadambi A, Izumi Y, Ang J, Yun C-O, Buerk DG, Huang PL, and Jain RK (2001) Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci USA 98:2604-2609.
11. Giannopoulou E, Katsoris P, Hatziapostolou M, Kardamakis D, Kotsaki E, Polytarchou C, Parthymou A, Papaioannou S, and Papadimitriou E (2001) X rays modulate extracellular matrix in vivo. Int J Cancer 94:690-698.
12. Giannopoulou E, Katsoris P, Parthymou A, Kardamakis D, and Papadimitriou E (2002a) Amifostine protects blood vessels from ionizing radiation. Anticancer Res 22:2821-2826.
13. Giannopoulou E, Katsoris P, Polytarchou C, and Papadimitriou E (2002b) Nitration of cytoskeletal proteins in the chicken embryo chorioallantoic membrane. Arch Biochem Biophys 400:188-198.
14. Grdina DJ, Kataoka Y, and Murley JS (2000) Amifostine: mechanisms of action underlying cytoprotection and chemoprevention. Drug Metab Drug Interact 16:237-279.
15. Grdina DJ, Kataoka Y, Murley JS, Hunter N, Weichselbaum RR, and Milas L (2002) Inhibition of spontaneous metastases formation by amifostine. Int J Cancer 97:135-141.
16. Ingber D and Folkman J (1988) Inhibition of angiogenesis through modulation of collagen metabolism. Lab Invest 59:44-51.
17. Kagan H (2000) Intra- and extracellular enzymes of collagen biosynthesis as biological and chemical targets in the control of fibrosis. Acta Trop 77:147-152.
18. Kim NH, Jung HH, Cha DR, and Choi DS (2000) Expression of vascular endothelial growth factor in response to high glucose in rat mesangial cells. J Endocrinol 165:617-624.
19. Kroll J and Waltenberger J (1998) VEGF-A induces expression ofeNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). Biochem Biophys Res Commun 252:743-746.
20. Lijnen HR (2002) Matrix metalloproteinases and cellular fibrinolytic activity. Biochemistry (Mosc) 67:107-115.
21. List AF and Gerner EW (2000) Amifostine: a tonic or toxin to myeloid progenitors. Leuk Res 24:1009-1011.
22. Liu SC, Murley JS, Woloschak G, and Grdina DJ (1997) Repression of c-myc gene expression by the thiol and disulfide forms of the cytoprotector amifostine. Carcinogenesis 18:2457-2459.
23. Meier T and Issels RD (1995) Degradation of 2-(3-aminopropylamino)-ethanediol (WR-1065) by Cu-dependent amine oxidases and influence on glutathione status of Chinese Hamster Ovary cells. Biochem Pharmacol 50:489-496.
24. Murley JS, Constantinou A, Kamath NS, and Grdina DJ (1997) WR-1065, an active metabolite of the cytoprotector amifostine, affects phosphorylation of topoisomerase IIα leading to changes in enzyme activity and cell cycle progression in CHO AA8 cells. Cell Prolif 30:283-294.
25. Murley JS, Kataoka Y, Hallahan DE, Roberts JC, and Grdina DJ (2001) Activation of NFκB and MnSOD gene expression by free radical scavengers in human microvascular endothelial cells. Free Radic Biol Med 30:1426-1439.
26. North S, El-Ghissassi F, Pluquet O, Verhaegh G, and Hainaut P (2000) The cytoprotective aminothiol WR1065 activates p21 waf-1 and down regulates cell cycle progression through a p53-dependent pathway. Oncogene 19:1206-1214.
27. Papadimitriou E, Polykratis A, Courty J, Koolwijk P, Heroult M, and Katsoris P (2001) HARP induces angiogenesis in vivo and in vitro: Implication of N or C terminal peptides. Biochem Biophys Res Commun 282:306-313.
28. Papadimitriou E, Unsworth BR, Maragoudakis ME, and Lelkes PI (1993) Time course and quantification of extracellular matrix maturation in the chick chorioallantoic membrane and in cultured endothelial cells. Endothelium 1:207-219.
29. Papapetropoulos A, Garcia-Gardena G, Madri JA, and Sessa WC (1997) Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Investig 100:3131-3139.
30. Pepper MS (2001) Extracellular proteolysis and angiogenesis. Thromb Haemostasis 86:346-355.
31. Pipili-Synetos E, Kritikou S, Papadimitriou E, Athanassiadou A, Flordellis C, and Maragoudakis ME (2000) Nitric oxide synthase expression, enzyme activity and NO production during angiogenesis in the chick chorioallantoic membrane. Br J Pharmacol 129:207-213.
32. Plasswilm L, Hanjalic A, Hoeper J, Cordes N, and Tannapfel A (1999) Microvessel density and endothelial cell proliferation after amifostine (Ethyol) administration in vivo. Anticancer Res 19:4241-4246.
33. Quinones HI, List AF, and Gerner EW (2002) Selective exclusion by the polyamine transporter as a mechanism for differential radioprotection of amifostine derivatives. Clin Cancer Res 8:1295-1300.
34. Romano MF, Lamberti A, Bisogni R, Garbi C, Pagnano AM, Auletta P, Tassone P, Turco MC, and Venuta S (1999) Amifostine inhibits hematapoietic progenitor cell apoptosis by activating NF-κB/Rel transcription factors. Blood 94:4060-4066.
35. Saito A, Kamii H, Kato I, Takasawa S, Kondo T, Chan PH, Okamoto H, and Yoshimoto T (2001) Transgenic CuZn-superoxide dismutase inhibits NO synthase induction in experimental subarachnoid hemorrhage. Stroke 32:1652-1657.
36. Santini V (2001) Amifostine: chemotherapeutic and radiotherapeutic protective effects. Exp Opin Pharmacother 2:479-489.
37. Shen H, Chen ZJ, Zilfou JT, Hopper E, Murphy M, and Tew KD (2001) Binding of the aminothiol WR-1065 to transcription factors influences cellular response to anticancer drugs. J Pharmacol Exp Ther 297:1067-1073.
38. Snyder RD and Grdina DJ (2000) Further evidence that the radioprotective aminothiol, WR-1065, catalytically inactivates mammalian topoisomerase II. Cancer Res 60:1186-1188.
39. Stromblad S and Cheresh D (1996) Cell adhesion and angiogenesis. Trends Cell Biol 6:462-467.
40. Sugishita Y, Takahashi T, Shimizu T, Yao A, Kinugawa K, Sugishita K, Harada K, Matsui H, and Nagai R (2000) Expression of genes encoding vascular endothelial growth factor and its Flk-1 receptor in the chick embryonic heart. J Mol Cell Cardiol 32:1039-1051.